

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		<i>Application Number</i>	10/541,394	
		<i>Filing Date</i>	July 1, 2005	
		<i>First Named Inventor</i>	Matti KIVIKKO	
		<i>Art Unit</i>	UNASSIGNED	
		<i>Examiner Name</i>	UNASSIGNED	
Sheet	1	of	1	
			<i>Attorney Docket Number</i>	06267.0128

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# known)	MM-DD-YYYY			
CPY	WO 99/66932		29 Dec. 1999			

NON PATENT LITERATURE DOCUMENTS			
Examiner initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
CRS		J. Lilleberg et al., "Dose-Range Study of a New Calcium Sensitizer, Levosimendan, In Patients with Left Ventricular Dysfunction," J. Cardiovasc Pharmacol, Vol. 26 (Suppl. 1), pages S63-S69 (1995)	
CRS		Stig Sundberg et al., "Hemodynamic and Neurohumoral Effects of Levosimendan, a New Calcium Sensitizer, at Rest and During Exercise in Healthy Men," The American Journal of Cardiology, Vol. 75, pages 1061-1066 (1995)	
CRS		Esa-Pekka Sandell et al., "Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart Failure," J Cardiovasc Pharmacol, Vol. 26 (Suppl. 1), pages S57-S62 (1995)	

Examiner Signature	<i>Chen J. Hu</i>	Date Considered	9/11/2007
-----------------------	-------------------	--------------------	-----------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>IDS Form PTO/SB/08: Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p>	<p><b>Complete If Known</b></p> <table border="1" style="margin-left: auto; margin-right: 0;"> <tr> <td>Application Number</td> <td>UNASSIGNED <i>10/541394</i></td> </tr> <tr> <td>Filing Date</td> <td>Filed Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Matti KIVIKKO</td> </tr> <tr> <td>Art Unit</td> <td>UNASSIGNED</td> </tr> <tr> <td>Examiner Name</td> <td>UNASSIGNED</td> </tr> <tr> <td>Attorney Docket Number</td> <td>06267.0128</td> </tr> </table>	Application Number	UNASSIGNED <i>10/541394</i>	Filing Date	Filed Herewith	First Named Inventor	Matti KIVIKKO	Art Unit	UNASSIGNED	Examiner Name	UNASSIGNED	Attorney Docket Number	06267.0128
Application Number	UNASSIGNED <i>10/541394</i>												
Filing Date	Filed Herewith												
First Named Inventor	Matti KIVIKKO												
Art Unit	UNASSIGNED												
Examiner Name	UNASSIGNED												
Attorney Docket Number	06267.0128												
Sheet	1	of	1										


## **U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications Is not required.**

## **FOREIGN PATENT DOCUMENTS**

## **NON PATENT LITERATURE DOCUMENTS**

NON-PAVNT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
GRS		XP00228338 & JP 04 368328 A (Teikoku Hormone Mfg Co Ltd) 21 December 1992 (1992-12-21) abstract, "Agent for treating chronic renal failure - contains 6-(4-acetyl-aminophenyl)-4,5-di:hydro-5-methyl-3(2H)-pyridazinone."	
CRS		Paul S. Pagel et al., "Pharmacology of Levosimendan: A New Myofilament Calcium Sensitizer," Cardiovascular Drug Reviews, Vol. 14, No. 3, pp. 286-316, 1996	
CRS		Paul S. Pagel et al., "Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs," British Journal of Pharmacology, Vol. 119, pp. 609-615, 1996	

Examiner Signature		Date Considered	9/11/2007
-----------------------	---	--------------------	-----------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.